Apr 11, 2017
A new study on the denosumab, a drug to treat postmenopausal osteoporosis, demonstrated reassuring information about all of its safety concerns, that include the short-term and long-term safety.
The study conclusively proved some adverse events which were reported in a pivotal clinical trial in women aged 60 to 90 years old treated for three years showed no tendency to increase after a further three years of treatment.
According to the study results published in Journal of Bone and Mineral Research, In addition, women who crossed over from three years of placebo to three years of denosumab experienced no increase in adverse effects compared with women treated for the initial three years.
"All of this is consistent with an excellent safety and tolerability profile for denosumab treatment for osteoporosis," said lead author of the study, Dr. Nelson Watts.
The authors also underlined that, especially in older women on long-term treatment, many if not all adverse events could be called "life events"--things that would have happened whether or not the person was participating in a clinical trial.
News Source: ANI
Image Sources: Shutterstock
Read More Health News